Key Takeaways from Two Post Hoc Analyses of the REACH2 Trial
Nelson J. Chao, MD, MBA, and Michael Grunwald, MD draw conclusions from two post hoc analyses of the REACH2 trial and share clinical pearls for community clinicians treating patients with acute Graft-Versus-Host Disease.
EP: 1.Understanding Acute Graft-Versus-Host Disease
EP: 2.Standard Treatments for Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
EP: 3.REACH 2 Post Hoc Analysis Review: and The Impact of Cytopenias on Patient Outcomes
EP: 4.Post Hoc Analysis Review: REACH2 and Early vs. Late Treatment with Ruxolitinib
Now Viewing
EP: 5.Key Takeaways from Two Post Hoc Analyses of the REACH2 Trial
EP: 6.Recap: Post Hoc Analysis Highlights Impact of Cytopenias on Response Rates in Acute GVHD
Related Videos
